Trial · NCT02964507
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase I-GSK525762 60 mg+FUL 500 mg (AI Failure) | 33 | |
| Overall Study | STARTED | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+AI Failure <12M) | 12 | |
| Overall Study | STARTED | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+ AI Failure >= 12M) | 42 | |
| Overall Study | STARTED | Phase I-GSK525762 60+FUL500mg CDK4/6+AI Failure>=12M Bone Only Disease | 7 | |
| Overall Study | STARTED | Phase I-GSK525762 80mg + FUL 500 mg (AI Failure) | 18 | |
| Overall Study | STARTED | Phase I-GSK525762 80 mg + FUL 500 mg (CDK4/6+AI Failure) | 11 | |
| Overall Study | STARTED | Phase II-GSK525762+FUL | 0 | |
| Overall Study | STARTED | Phase II-Placebo+FUL | 0 | |
| Overall Study | COMPLETED | Phase I-GSK525762 60 mg+FUL 500 mg (AI Failure) | 7 | |
| Overall Study | COMPLETED | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+AI Failure <12M) | 1 | |
| Overall Study | COMPLETED | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+ AI Failure >= 12M) | 17 | |
| Overall Study | COMPLETED | Phase I-GSK525762 60+FUL500mg CDK4/6+AI Failure>=12M Bone Only Disease | 1 | |
| Overall Study | COMPLETED | Phase I-GSK525762 80mg + FUL 500 mg (AI Failure) | 2 | |
| Overall Study | COMPLETED | Phase I-GSK525762 80 mg + FUL 500 mg (CDK4/6+AI Failure) | 3 | |
| Overall Study | COMPLETED | Phase II-GSK525762+FUL | 0 | |
| Overall Study | COMPLETED | Phase II-Placebo+FUL | 0 | |
| Overall Study | NOT COMPLETED | Phase I-GSK525762 60 mg+FUL 500 mg (AI Failure) | 26 | |
| Overall Study | NOT COMPLETED | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+AI Failure <12M) | 11 | |
| Overall Study | NOT COMPLETED | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+ AI Failure >= 12M) | 25 | |
| Overall Study | NOT COMPLETED | Phase I-GSK525762 60+FUL500mg CDK4/6+AI Failure>=12M Bone Only Disease | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02964507/flow